Research Article Details

Article ID: A03756
PMID: 33875327
Source: Trends Endocrinol Metab
Title: RIPK1 targeting protects against obesity and atherosclerosis.
Abstract: Unhealthy lifestyles and dietary habits often lead to diet-associated inflammatory diseases such as obesity and atherosclerosis. Recent studies have provided novel insight into the role of RIPK1 in inflammation and metabolism. RIPK1 silencing can reduce diet-induced obesity, nonalcoholic fatty liver disease (NAFLD), and atherosclerosis by reducing inflammation, lipid synthesis, and inflammasome activation. Targeting RIPK1 may therefore attenuate chronic metabolic disease and would likely be therapeutic.
DOI: 10.1016/j.tem.2021.03.009